Related Experiment Video

Updated: Feb 19, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

The combination of checkpoint immunotherapy and targeted therapy in cancer

Niki Karachaliou1, Maria Gonzalez-Cao2, Aaron Sosa1

  • 1Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain.

Annals of Translational Medicine
|November 9, 2017
PubMed

Insights

Targeted therapies and immunotherapies have advanced cancer treatment, improving survival for metastatic melanoma and non-small cell lung cancer (NSCLC). Combining these approaches is a key focus for further clinical development.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Metastatic melanoma and non-small cell lung cancer (NSCLC) treatment has been revolutionized by targeted therapies and immunotherapies.
  • These therapies have significantly improved median overall survival rates in patients.
  • Targeted therapies offer transient responses in some patients, while immunotherapy can provide durable responses in others.

Purpose of the Study:

  • To review preclinical and clinical data on combining targeted therapies with immunotherapy.
  • To focus on the efficacy of these combinations in melanoma and NSCLC.

Main Methods:

  • Review of existing preclinical studies.
  • Analysis of clinical trial data.

Main Results:

  • Combination therapies show promise in enhancing antitumor immunity and inhibiting oncogenic pathways.
  • Data suggests potential for improved patient outcomes when combining targeted agents with immune checkpoint inhibitors.

Conclusions:

  • Combining targeted therapies and immunotherapy represents a promising strategy for managing metastatic melanoma and NSCLC.
  • Further clinical development is warranted to optimize combination regimens and patient selection for these advanced cancers.
Keywords:
BRAF, epidermal growth factor receptor (EGFR)Immune checkpoint blockade (ICB)lung cancermelanomatargeted therapies

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.7K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.8K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K